世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

膀胱癌治療薬の市場調査。ナノテクノロジーの活用が今後注目される


Market Study on Bladder Cancer Treatment Drugs: Use of Nanotechnology to Gain Prominence Going Forward

膀胱癌治療薬市場。レポート範囲 Persistence Market Researchが発行する世界の膀胱癌治療薬市場に関する最新市場レポートは、機会や現在の市場シナリオを評価し、2022年から2032年の予測期間において市場に関... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Persistence Market Research
パーシスタンスマーケットリサーチ
2022年10月4日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
250 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

膀胱癌治療薬市場。レポート範囲

Persistence Market Researchが発行する世界の膀胱癌治療薬市場に関する最新市場レポートは、機会や現在の市場シナリオを評価し、2022年から2032年の予測期間において市場に関与する対応セグメントに関する洞察と最新情報を提供します。主要な市場力学の詳細な評価や、市場構造に関する包括的な情報を提供しています。2022-2032年の予測期間中に市場がどのように成長すると予想されるかについての詳細な洞察が含まれています。

本レポートの主な目的は、膀胱癌治療薬に関連するグローバルビジネスの変革を支えている市場の機会に関する洞察を提供することである。常に変動する経済において、読者が市場の分析と評価をより良く理解し、この空間における有利な機会を発見できるように、全体的な予測のための複合年間成長率(CAGR)に加えて、推定(Y-oY)対前年成長率を提供することを考慮することは非常に重要である。

また、本レポートでは、市場規模の推定とそれに対応する絶対額での収益予測も行っています。また、市場の将来的な動向に基づいた実用的な洞察も提供しています。さらに、世界の膀胱癌治療薬市場における新規および新興のプレーヤーは、効果的なビジネス上の意思決定のために本調査で提示された情報を利用することができ、世界市場だけでなく、そのビジネスにも勢いを与えることになるでしょう。

本調査は、膀胱癌治療薬市場のメーカー、サプライヤー、流通業者、投資家に関連するものです。すべての関係者、業界専門家、研究者、ジャーナリスト、ビジネス研究者は、本レポートで表現された情報とデータを活用することができます。

主な市場セグメント

Persistence Market Research社の調査レポート「膀胱癌治療薬の世界市場」は、タイプ、用途、流通チャネル、地域の4つのセグメントに分けて情報を提供しています。

タイプ

非筋肉浸潤性膀胱癌
筋層浸潤性膀胱癌
応用分野

低悪性度腫瘍
高悪性度腫瘍
販売チャネル

病院薬局
小売店
その他
地域別

北アメリカ
ラテンアメリカ
欧州
南アジア・太平洋
東アジア
中近東・アフリカ
本調査で回答した主な質問

予測期間中に最も高い市場シェアを占めるのはどの地域か?
最も高い成長(CAGR)を遂げているのはどの地域か?
世界の膀胱癌治療薬産業に影響を与えている要因は何か?
市場に影響を及ぼしている世界的なトレンドは何か?
市場の様々な地域で機会を捉えるために、新興プレイヤーはどのような戦略を採用しなければならないか?
世界の膀胱癌治療薬市場の構造は?
調査方法

Persistence Market Research社は、お客様に偏りのない市場調査ソリューションを提供することに努めています。同社は、本レポートに含まれるデータの控除について、堅牢な方法論に従っています。世界の膀胱癌治療薬市場に関する広範な調査を実施し、市場の将来の成長要因に関する結論を得るために、独自の調査方法論を活用しています。調査手法は、一次調査手法と二次調査手法の組み合わせで構成されており、本レポートの結論の正確性と信頼性を保証しています。

需要サイドのアプローチで対象製品の売上高を推定し、次に供給サイドのアプローチであらかじめ定義された期間における生成価値、主要トレンド、イベントに関する詳細な評価を行います。

この手法は、Persistence Market Researchが世界市場のセグメント化のために考慮する、北米、中南米、ヨーロッパ、南アジア・太平洋、東アジア、中東・アフリカの6地域以上の現地ソースからのインプットに基づく、標準の市場構造、手法、定義に基づいています。統計、特性、差異を地域レベルで収集し、同じレベルで集計し、世界レベルで統合して、世界市場の測定値を作成しています。

主な調査対象は以下の通りです。

プライマリーリサーチ
セカンダリーリサーチ
貿易調査
ソーシャルメディアリサーチ

ページTOPに戻る


目次

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Technology Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. Product USPs / Features

    4.3. Strategic Promotional Strategies

5. Global Bladder Cancer Treatment Drugs Market Demand Analysis 2017–2021 and Forecast, 2022–2032

    5.1. Historical Market Volume (Tons) Analysis, 2017–2021

    5.2. Current and Future Market Volume (Tons) Projections, 2022–2032

    5.3. Y-o-Y Growth Trend Analysis

6. Global Bladder Cancer Treatment Drugs Market - Pricing Analysis

    6.1. Regional Pricing Analysis By Type

    6.2. Global Average Pricing Analysis Benchmark

7. Global Bladder Cancer Treatment Drugs Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Market Background

    8.1. Macro-Economic Factors

        8.1.1. Global GDP Growth Outlook

        8.1.2. Global Industry Value Added Overview

        8.1.3. Global Infrastructure Investment Overview

        8.1.4. Global Construction Spending Analysis

        8.1.5. Other Macro Economic Factors

    8.2. Forecast Factors - Relevance & Impact

        8.2.1. Top Companies Historical Growth

        8.2.2. GDP Growth forecast

        8.2.3. Construction Industry forecast

        8.2.4. Distribution Channel Growth Outlook

        8.2.5. Collaboration Activities

    8.3. Value Chain

        8.3.1. Raw Material Suppliers

        8.3.2. List of Manufacturers

        8.3.3. List of Distributors

    8.4. COVID-19 Crisis – Impact Assessment

        8.4.1. Current Statistics

        8.4.2. Short-Mid-Long Term Outlook

        8.4.3. Likely Rebound

    8.5. Market Dynamics

        8.5.1. Drivers

        8.5.2. Restraints

        8.5.3. Opportunity Analysis

        8.5.4. Trends

9. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, by Type

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017–2021

    9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Type 2022–2032

        9.3.1. Non-Muscle-Invasive Bladder Cancer

        9.3.2. Muscle-Invasive Bladder Cancer

    9.4. Market Attractiveness Analysis by Type

10. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, By Application

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) and Volume Analysis By Application, 2017–2021

    10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Application, 2022–2032

        10.3.1. Low-Grade Tumors

        10.3.2. High-Grade Tumors

    10.4. Market Attractiveness Analysis By Application

11. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017–2021

    11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022–2032

        11.3.1. Hospital Pharmacy

        11.3.2. Retail Pharmacy

        11.3.3. Others

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, by Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021

    12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022–2032

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia and Pacific

        12.3.6. Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032

        13.4.1. By Country

            13.4.1.1. U.S.

            13.4.1.2. Canada

        13.4.2. By Type

        13.4.3. By Application

        13.4.4. By Distribution Channel

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Type

        13.5.3. By Application

        13.5.4. By Distribution Channel

    13.6. Market Trends

    13.7. Key Market Participants - Intensity Mapping

    13.8. Drivers and Restraints - Impact Analysis

14. Latin America Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        14.4.1. By Country

            14.4.1.1. Brazil

            14.4.1.2. Mexico

            14.4.1.3. Rest of Latin America

        14.4.2. By Type

        14.4.3. By Application

        14.4.4. By Distribution Channel

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Type

        14.5.3. By Application

        14.5.4. By Distribution Channel

    14.6. Market Trends

    14.7. Key Market Participants - Intensity Mapping

    14.8. Drivers and Restraints - Impact Analysis

15. Europe Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021

    15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        15.4.1. By Country

            15.4.1.1. Germany

            15.4.1.2. Italy

            15.4.1.3. France

            15.4.1.4. U.K.

            15.4.1.5. Spain

            15.4.1.6. BENELUX

            15.4.1.7. Russia

            15.4.1.8. Rest of Europe

        15.4.2. By Type

        15.4.3. By Application

        15.4.4. By Distribution Channel

    15.5. Market Attractiveness Analysis

        15.5.1. By Country

        15.5.2. By Type

        15.5.3. By Application

        15.5.4. By Distribution Channel

    15.6. Market Trends

    15.7. Key Market Participants - Intensity Mapping

    15.8. Drivers and Restraints - Impact Analysis

16. South Asia and Pacific Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Pricing Analysis

    16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        16.4.1. By Country

            16.4.1.1. India

            16.4.1.2. ASEAN

            16.4.1.3. Oceania

            16.4.1.4. Rest of South Asia & Pacific

        16.4.2. By Type

        16.4.3. By Application

        16.4.4. By Distribution Channel

    16.5. Market Attractiveness Analysis

        16.5.1. By Country

        16.5.2. By Type

        16.5.3. By Application

        16.5.4. By Distribution Channel

    16.6. Market Trends

    16.7. Key Market Participants - Intensity Mapping

    16.8. Drivers and Restraints - Impact Analysis

17. East Asia Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Pricing Analysis

    17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        17.4.1. By Country

            17.4.1.1. China

            17.4.1.2. Japan

            17.4.1.3. South Korea

        17.4.2. By Type

        17.4.3. By Application

        17.4.4. By Distribution Channel

    17.5. Market Attractiveness Analysis

        17.5.1. By Country

        17.5.2. By Type

        17.5.3. By Application

        17.5.4. By Distribution Channel

    17.6. Market Trends

    17.7. Key Market Participants - Intensity Mapping

    17.8. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    18.1. Introduction

    18.2. Pricing Analysis

    18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        18.4.1. By Country

            18.4.1.1. GCC Countries

            18.4.1.2. Turkey

            18.4.1.3. Northern Africa

            18.4.1.4. South Africa

            18.4.1.5. Rest of Middle East and Africa

        18.4.2. By Type

        18.4.3. By Application

        18.4.4. By Distribution Channel

    18.5. Market Attractiveness Analysis

        18.5.1. By Country

        18.5.2. By Type

        18.5.3. By Application

        18.5.4. By Distribution Channel

    18.6. Market Trends

    18.7. Key Market Participants - Intensity Mapping

    18.8. Drivers and Restraints - Impact Analysis

19. Emerging Countries Bladder Cancer Treatment Drugs Market Analysis

    19.1. Introduction

        19.1.1. Market Value Proportion Analysis, By Key Countries

        19.1.2. Global Vs. Country Growth Comparison

    19.2. U.S. Bladder Cancer Treatment Drugs Market Analysis

        19.2.1. By Type

        19.2.2. By Application

        19.2.3. By Distribution Channel

    19.3. Canada Bladder Cancer Treatment Drugs Market Analysis

        19.3.1. By Type

        19.3.2. By Application

        19.3.3. By Distribution Channel

    19.4. Mexico Bladder Cancer Treatment Drugs Market Analysis

        19.4.1. By Type

        19.4.2. By Application

        19.4.3. By Distribution Channel

    19.5. Brazil Bladder Cancer Treatment Drugs Market Analysis

        19.5.1. By Type

        19.5.2. By Application

        19.5.3. By Distribution Channel

    19.6. Germany Bladder Cancer Treatment Drugs Market Analysis

        19.6.1. By Type

        19.6.2. By Application

        19.6.3. By Distribution Channel

    19.7. Italy Bladder Cancer Treatment Drugs Market Analysis

        19.7.1. By Type

        19.7.2. By Application

        19.7.3. By Distribution Channel

    19.8. France Bladder Cancer Treatment Drugs Market Analysis

        19.8.1. By Type

        19.8.2. By Application

        19.8.3. By Distribution Channel

    19.9. U.K. Bladder Cancer Treatment Drugs Market Analysis

        19.9.1. By Type

        19.9.2. By Application

        19.9.3. By Distribution Channel

    19.10. Spain Bladder Cancer Treatment Drugs Market Analysis

        19.10.1. By Type

        19.10.2. By Application

        19.10.3. By Distribution Channel

    19.11.  BENELUX Bladder Cancer Treatment Drugs Market Analysis

        19.11.1. By Type

        19.11.2. By Application

        19.11.3. By Distribution Channel

    19.12. Russia Bladder Cancer Treatment Drugs Market Analysis

        19.12.1. By Type

        19.12.2. By Application

        19.12.3. By Distribution Channel

    19.13. China Bladder Cancer Treatment Drugs Market Analysis

        19.13.1. By Type

        19.13.2. By Application

        19.13.3. By Distribution Channel

    19.14. Japan Bladder Cancer Treatment Drugs Market Analysis

        19.14.1. By Type

        19.14.2. By Application

        19.14.3. By Distribution Channel

    19.15. S. Korea Bladder Cancer Treatment Drugs Market Analysis

        19.15.1. By Type

        19.15.2. By Application

        19.15.3. By Distribution Channel

    19.16. India Bladder Cancer Treatment Drugs Market Analysis

        19.16.1. By Type

        19.16.2. By Application

        19.16.3. By Distribution Channel

    19.17. ASEAN Bladder Cancer Treatment Drugs Market Analysis

        19.17.1. By Type

        19.17.2. By Application

        19.17.3. By Distribution Channel

    19.18. Australia and New Zealand Bladder Cancer Treatment Drugs Market Analysis

        19.18.1. By Type

        19.18.2. By Application

        19.18.3. By Distribution Channel

    19.19.  GCC Countries Bladder Cancer Treatment Drugs Market Analysis

        19.19.1. By Type

        19.19.2. By Application

        19.19.3. By Distribution Channel

    19.20. Turkey Bladder Cancer Treatment Drugs Market Analysis

        19.20.1. By Type

        19.20.2. By Application

        19.20.3. By Distribution Channel

    19.21. Northern Africa Bladder Cancer Treatment Drugs Market Analysis

        19.21.1. By Type

        19.21.2. By Application

        19.21.3. By Distribution Channel

    19.22. South Africa Bladder Cancer Treatment Drugs Market Analysis

        19.22.1. By Type

        19.22.2. By Application

        19.22.3. By Distribution Channel

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)

    20.2. Market Share Analysis of Top Players

    20.3. Market Presence Analysis

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive

        21.3.1. GlaxoSmithKline plc

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.1.4. Sales Footprint

            21.3.1.5. Strategy Overview

        21.3.2. Novartis International AG

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.2.4. Sales Footprint

            21.3.2.5. Strategy Overview

        21.3.3. Sanofi S.A

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.3.4. Sales Footprint

            21.3.3.5. Strategy Overview

        21.3.4. Pfizer Inc.

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.4.4. Sales Footprint

            21.3.4.5. Strategy Overview

        21.3.5. Eli Lilly and Co

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.5.4. Sales Footprint

            21.3.5.5. Strategy Overview

        21.3.6. AstraZeneca plc

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.6.4. Sales Footprint

            21.3.6.5. Strategy Overview

        21.3.7. Bristol-Myers Squibb

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.7.4. Sales Footprint

            21.3.7.5. Strategy Overview

        21.3.8. F., Celgene Corporation

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.8.4. Sales Footprint

            21.3.8.5. Strategy Overview

        21.3.9. Hoffmann-La Roche AG

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.9.4. Sales Footprint

            21.3.9.5. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology

 

ページTOPに戻る


 

Summary

Bladder Cancer Treatment Drugs Market: Report Scope

The latest market report by Persistence Market Research on the global bladder cancer treatment drugs market evaluates the opportunities and current market scenario, providing insights and updates about corresponding segments involved in the market for the forecast period of 2022-2032. The report provides detailed assessment of key market dynamics, and comprehensive information about the structure of the market. This study contains detailed insights into how the market is anticipated to grow during the forecast period of 2022-2032.

The primary objective of the report is to provide insights regarding opportunities in the market that are supporting the transformation of global businesses associated with Bladder Cancer Treatment Drugs. It is very important to consider that, in an ever-wavering economy, we provide estimated (Y-o-Y) year-on-year growth rate in addition to compound annual growth rate (CAGR) for overall forecasts, to enable readers better understand the analysis and evaluation of the market, and to discover lucrative opportunities in this space.

This report also provides an estimate of market size and corresponding revenue forecasts carried out in terms of absolute $ opportunity. It also offers actionable insights based on the future trends in the market. Furthermore, new and emerging players in the global bladder cancer treatment drugs market can make use of the information presented in the study for effective business decisions, which will provide momentum to their businesses as well as the global market.

The study is relevant for manufacturers, suppliers, distributors, and investors in the bladder cancer treatment drugs market. All stakeholders, as well as industry experts, researchers, journalists, and business researchers can leverage the information and data represented in the report.

Key Market Segments

Persistence Market Research’s report on the global bladder cancer treatment drugs market offers information divided into four segments – type, application, distribution channel, and region.

Type

Non-Muscle-Invasive Bladder Cancer
Muscle-Invasive Bladder Cancer
Application

Low-Grade Tumors
High-Grade Tumors
Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Others
Region

North America
Latin America
Europe
South Asia and Pacific
East Asia
Middle East and Africa
Key Questions Answered in Study

Which region will hold the highest market share over the forecast period?
Which region is experiencing the highest growth (CAGR)?
Which factors are impacting the global bladder cancer treatment drugs industry?
What are the global trends impacting the market?
What strategies must emerge players adopt to capture opportunities in various regions in the market?
What is the structure of the global bladder cancer treatment drugs market?
Research Methodology

Persistence Market Research is committed to providing unbiased market research solutions to its clients. The company follows a robust methodology for the deduction of data included in this report. A unique research methodology is utilized to conduct extensive research on the global bladder cancer treatment drugs market, and reach conclusions about the future growth factors of the market. The research methodology comprises primary research methods coupled with secondary research methods, which ensures the accuracy and reliability of the conclusions in this report.

A demand-side approach is followed to estimate the sales of target products, followed by an in-depth supply-side assessment of value generated, key trends, and events over a predefined period.

This methodology is based on standard market structures, methods, and definitions that are based on inputs from local sources in over six regions - North America, Latin America, Europe, South Asia and Pacific, East Asia, and the Middle East & Africa, which Persistence Market Research considers for segmenting the global market. Statistics, characteristics, and variances are collected at a regional level, aggregated at the same level, and then synthesized at a worldwide level, to create global market measurements.

Our main sources of research include:

Primary Research
Secondary Research
Trade Research
Social Media Research



ページTOPに戻る


Table of Contents

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Technology Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. Product Adoption / Usage Analysis

    4.2. Product USPs / Features

    4.3. Strategic Promotional Strategies

5. Global Bladder Cancer Treatment Drugs Market Demand Analysis 2017–2021 and Forecast, 2022–2032

    5.1. Historical Market Volume (Tons) Analysis, 2017–2021

    5.2. Current and Future Market Volume (Tons) Projections, 2022–2032

    5.3. Y-o-Y Growth Trend Analysis

6. Global Bladder Cancer Treatment Drugs Market - Pricing Analysis

    6.1. Regional Pricing Analysis By Type

    6.2. Global Average Pricing Analysis Benchmark

7. Global Bladder Cancer Treatment Drugs Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2017–2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Market Background

    8.1. Macro-Economic Factors

        8.1.1. Global GDP Growth Outlook

        8.1.2. Global Industry Value Added Overview

        8.1.3. Global Infrastructure Investment Overview

        8.1.4. Global Construction Spending Analysis

        8.1.5. Other Macro Economic Factors

    8.2. Forecast Factors - Relevance & Impact

        8.2.1. Top Companies Historical Growth

        8.2.2. GDP Growth forecast

        8.2.3. Construction Industry forecast

        8.2.4. Distribution Channel Growth Outlook

        8.2.5. Collaboration Activities

    8.3. Value Chain

        8.3.1. Raw Material Suppliers

        8.3.2. List of Manufacturers

        8.3.3. List of Distributors

    8.4. COVID-19 Crisis – Impact Assessment

        8.4.1. Current Statistics

        8.4.2. Short-Mid-Long Term Outlook

        8.4.3. Likely Rebound

    8.5. Market Dynamics

        8.5.1. Drivers

        8.5.2. Restraints

        8.5.3. Opportunity Analysis

        8.5.4. Trends

9. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, by Type

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2017–2021

    9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Type 2022–2032

        9.3.1. Non-Muscle-Invasive Bladder Cancer

        9.3.2. Muscle-Invasive Bladder Cancer

    9.4. Market Attractiveness Analysis by Type

10. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, By Application

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) and Volume Analysis By Application, 2017–2021

    10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Application, 2022–2032

        10.3.1. Low-Grade Tumors

        10.3.2. High-Grade Tumors

    10.4. Market Attractiveness Analysis By Application

11. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) and Volume Analysis By Distribution Channel, 2017–2021

    11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Distribution Channel 2022–2032

        11.3.1. Hospital Pharmacy

        11.3.2. Retail Pharmacy

        11.3.3. Others

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032, by Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2017–2021

    12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2022–2032

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia and Pacific

        12.3.6. Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America Bladder Cancer Treatment Drugs Market Analysis 2017–2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022–2032

        13.4.1. By Country

            13.4.1.1. U.S.

            13.4.1.2. Canada

        13.4.2. By Type

        13.4.3. By Application

        13.4.4. By Distribution Channel

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Type

        13.5.3. By Application

        13.5.4. By Distribution Channel

    13.6. Market Trends

    13.7. Key Market Participants - Intensity Mapping

    13.8. Drivers and Restraints - Impact Analysis

14. Latin America Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        14.4.1. By Country

            14.4.1.1. Brazil

            14.4.1.2. Mexico

            14.4.1.3. Rest of Latin America

        14.4.2. By Type

        14.4.3. By Application

        14.4.4. By Distribution Channel

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Type

        14.5.3. By Application

        14.5.4. By Distribution Channel

    14.6. Market Trends

    14.7. Key Market Participants - Intensity Mapping

    14.8. Drivers and Restraints - Impact Analysis

15. Europe Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017-2021

    15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        15.4.1. By Country

            15.4.1.1. Germany

            15.4.1.2. Italy

            15.4.1.3. France

            15.4.1.4. U.K.

            15.4.1.5. Spain

            15.4.1.6. BENELUX

            15.4.1.7. Russia

            15.4.1.8. Rest of Europe

        15.4.2. By Type

        15.4.3. By Application

        15.4.4. By Distribution Channel

    15.5. Market Attractiveness Analysis

        15.5.1. By Country

        15.5.2. By Type

        15.5.3. By Application

        15.5.4. By Distribution Channel

    15.6. Market Trends

    15.7. Key Market Participants - Intensity Mapping

    15.8. Drivers and Restraints - Impact Analysis

16. South Asia and Pacific Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Pricing Analysis

    16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        16.4.1. By Country

            16.4.1.1. India

            16.4.1.2. ASEAN

            16.4.1.3. Oceania

            16.4.1.4. Rest of South Asia & Pacific

        16.4.2. By Type

        16.4.3. By Application

        16.4.4. By Distribution Channel

    16.5. Market Attractiveness Analysis

        16.5.1. By Country

        16.5.2. By Type

        16.5.3. By Application

        16.5.4. By Distribution Channel

    16.6. Market Trends

    16.7. Key Market Participants - Intensity Mapping

    16.8. Drivers and Restraints - Impact Analysis

17. East Asia Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Pricing Analysis

    17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        17.4.1. By Country

            17.4.1.1. China

            17.4.1.2. Japan

            17.4.1.3. South Korea

        17.4.2. By Type

        17.4.3. By Application

        17.4.4. By Distribution Channel

    17.5. Market Attractiveness Analysis

        17.5.1. By Country

        17.5.2. By Type

        17.5.3. By Application

        17.5.4. By Distribution Channel

    17.6. Market Trends

    17.7. Key Market Participants - Intensity Mapping

    17.8. Drivers and Restraints - Impact Analysis

18. Middle East and Africa Bladder Cancer Treatment Drugs Market Analysis 2017-2021 and Forecast 2022-2032

    18.1. Introduction

    18.2. Pricing Analysis

    18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2017–2021

    18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2022-2032

        18.4.1. By Country

            18.4.1.1. GCC Countries

            18.4.1.2. Turkey

            18.4.1.3. Northern Africa

            18.4.1.4. South Africa

            18.4.1.5. Rest of Middle East and Africa

        18.4.2. By Type

        18.4.3. By Application

        18.4.4. By Distribution Channel

    18.5. Market Attractiveness Analysis

        18.5.1. By Country

        18.5.2. By Type

        18.5.3. By Application

        18.5.4. By Distribution Channel

    18.6. Market Trends

    18.7. Key Market Participants - Intensity Mapping

    18.8. Drivers and Restraints - Impact Analysis

19. Emerging Countries Bladder Cancer Treatment Drugs Market Analysis

    19.1. Introduction

        19.1.1. Market Value Proportion Analysis, By Key Countries

        19.1.2. Global Vs. Country Growth Comparison

    19.2. U.S. Bladder Cancer Treatment Drugs Market Analysis

        19.2.1. By Type

        19.2.2. By Application

        19.2.3. By Distribution Channel

    19.3. Canada Bladder Cancer Treatment Drugs Market Analysis

        19.3.1. By Type

        19.3.2. By Application

        19.3.3. By Distribution Channel

    19.4. Mexico Bladder Cancer Treatment Drugs Market Analysis

        19.4.1. By Type

        19.4.2. By Application

        19.4.3. By Distribution Channel

    19.5. Brazil Bladder Cancer Treatment Drugs Market Analysis

        19.5.1. By Type

        19.5.2. By Application

        19.5.3. By Distribution Channel

    19.6. Germany Bladder Cancer Treatment Drugs Market Analysis

        19.6.1. By Type

        19.6.2. By Application

        19.6.3. By Distribution Channel

    19.7. Italy Bladder Cancer Treatment Drugs Market Analysis

        19.7.1. By Type

        19.7.2. By Application

        19.7.3. By Distribution Channel

    19.8. France Bladder Cancer Treatment Drugs Market Analysis

        19.8.1. By Type

        19.8.2. By Application

        19.8.3. By Distribution Channel

    19.9. U.K. Bladder Cancer Treatment Drugs Market Analysis

        19.9.1. By Type

        19.9.2. By Application

        19.9.3. By Distribution Channel

    19.10. Spain Bladder Cancer Treatment Drugs Market Analysis

        19.10.1. By Type

        19.10.2. By Application

        19.10.3. By Distribution Channel

    19.11.  BENELUX Bladder Cancer Treatment Drugs Market Analysis

        19.11.1. By Type

        19.11.2. By Application

        19.11.3. By Distribution Channel

    19.12. Russia Bladder Cancer Treatment Drugs Market Analysis

        19.12.1. By Type

        19.12.2. By Application

        19.12.3. By Distribution Channel

    19.13. China Bladder Cancer Treatment Drugs Market Analysis

        19.13.1. By Type

        19.13.2. By Application

        19.13.3. By Distribution Channel

    19.14. Japan Bladder Cancer Treatment Drugs Market Analysis

        19.14.1. By Type

        19.14.2. By Application

        19.14.3. By Distribution Channel

    19.15. S. Korea Bladder Cancer Treatment Drugs Market Analysis

        19.15.1. By Type

        19.15.2. By Application

        19.15.3. By Distribution Channel

    19.16. India Bladder Cancer Treatment Drugs Market Analysis

        19.16.1. By Type

        19.16.2. By Application

        19.16.3. By Distribution Channel

    19.17. ASEAN Bladder Cancer Treatment Drugs Market Analysis

        19.17.1. By Type

        19.17.2. By Application

        19.17.3. By Distribution Channel

    19.18. Australia and New Zealand Bladder Cancer Treatment Drugs Market Analysis

        19.18.1. By Type

        19.18.2. By Application

        19.18.3. By Distribution Channel

    19.19.  GCC Countries Bladder Cancer Treatment Drugs Market Analysis

        19.19.1. By Type

        19.19.2. By Application

        19.19.3. By Distribution Channel

    19.20. Turkey Bladder Cancer Treatment Drugs Market Analysis

        19.20.1. By Type

        19.20.2. By Application

        19.20.3. By Distribution Channel

    19.21. Northern Africa Bladder Cancer Treatment Drugs Market Analysis

        19.21.1. By Type

        19.21.2. By Application

        19.21.3. By Distribution Channel

    19.22. South Africa Bladder Cancer Treatment Drugs Market Analysis

        19.22.1. By Type

        19.22.2. By Application

        19.22.3. By Distribution Channel

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)

    20.2. Market Share Analysis of Top Players

    20.3. Market Presence Analysis

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive

        21.3.1. GlaxoSmithKline plc

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.1.4. Sales Footprint

            21.3.1.5. Strategy Overview

        21.3.2. Novartis International AG

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.2.4. Sales Footprint

            21.3.2.5. Strategy Overview

        21.3.3. Sanofi S.A

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.3.4. Sales Footprint

            21.3.3.5. Strategy Overview

        21.3.4. Pfizer Inc.

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.4.4. Sales Footprint

            21.3.4.5. Strategy Overview

        21.3.5. Eli Lilly and Co

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.5.4. Sales Footprint

            21.3.5.5. Strategy Overview

        21.3.6. AstraZeneca plc

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.6.4. Sales Footprint

            21.3.6.5. Strategy Overview

        21.3.7. Bristol-Myers Squibb

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.7.4. Sales Footprint

            21.3.7.5. Strategy Overview

        21.3.8. F., Celgene Corporation

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.8.4. Sales Footprint

            21.3.8.5. Strategy Overview

        21.3.9. Hoffmann-La Roche AG

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            21.3.9.4. Sales Footprint

            21.3.9.5. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療機器)の最新刊レポート

Persistence Market Research社の医療・製薬・メディカルデバイス分野での最新刊レポート


よくあるご質問


Persistence Market Research社はどのような調査会社ですか?


パーシスタンスマーケットリサーチ(Persistence Market Research/PMR)は独自の方法論を用いたデータ解析と市場調査をベースに広範な産業調査報告書とカスタム調査を提供しています... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/23 10:26

157.72 円

164.94 円

201.11 円

ページTOPに戻る